ADMA Biologics, Inc.

NasdaqGM ADMA

ADMA Biologics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -7.23 M

ADMA Biologics, Inc. Net Cash Used For Investing Activities is USD -7.23 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 1.23% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

ADMA Biologics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -7.32 M, a 47.09% change year over year.
ADMA Biologics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -13.84 M, a -3.01% change year over year.
ADMA Biologics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -13.43 M, a -25.31% change year over year.
ADMA Biologics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -10.72 M, a -253.05% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGM: ADMA

ADMA Biologics, Inc.

CEO	Mr. Adam S. Grossman
IPO Date	Oct. 17, 2013
Location	United States
Headquarters	465 State Route 17
Employees	624
Sector	Health Care
Industries Pharmaceuticals Biotechnology Vaccines

Description

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Key trends

Past 5 years